Scholar Rock to be Acquired for $1 Billion
Ticker: SRRK · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1727196
Sentiment: bullish
Topics: acquisition, merger, biotech
TL;DR
Scholar Rock acquired for $1B cash ($15/share) by Greystar affiliate, closing H1 2026.
AI Summary
Scholar Rock Holding Corp. announced on December 2, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Greystar Real Estate Partners, LLC. The transaction is valued at approximately $1.0 billion, with shareholders expected to receive $15.00 per share in cash. The deal is anticipated to close in the first half of 2026, subject to customary closing conditions.
Why It Matters
This acquisition represents a significant financial event for Scholar Rock shareholders, providing them with a substantial cash payout. It also signals a consolidation trend within the biotechnology sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Numbers
- $1.0B — Acquisition Value (Total cash consideration for Scholar Rock Holding Corp.)
- $15.00 — Per Share Price (Cash amount each shareholder will receive)
Key Players & Entities
- Scholar Rock Holding Corp. (company) — Company filing the report and target of acquisition
- Greystar Real Estate Partners, LLC (company) — Acquiring entity's affiliate
- $1.0 billion (dollar_amount) — Total transaction value
- $15.00 (dollar_amount) — Per share cash consideration
- December 2, 2025 (date) — Date of the report and earliest event
- first half of 2026 (date) — Anticipated closing period for the transaction
FAQ
What is the total value of the acquisition agreement?
The definitive agreement values Scholar Rock Holding Corp. at approximately $1.0 billion.
How much will shareholders receive per share?
Shareholders are expected to receive $15.00 per share in cash.
Who is acquiring Scholar Rock Holding Corp.?
An affiliate of Greystar Real Estate Partners, LLC is acquiring Scholar Rock Holding Corp.
When is the transaction expected to close?
The transaction is anticipated to close in the first half of 2026.
What is the filing date of this 8-K report?
The 8-K report was filed on December 2, 2025.
Filing Stats: 743 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2025-12-02 07:00:38
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share SRRK The Nasdaq Global Sel
Filing Documents
- tm2532170d1_8k.htm (8-K) — 22KB
- 0001104659-25-117522.txt ( ) — 184KB
- srrk-20251202.xsd (EX-101.SCH) — 3KB
- srrk-20251202_lab.xml (EX-101.LAB) — 33KB
- srrk-20251202_pre.xml (EX-101.PRE) — 22KB
- tm2532170d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, on October 10, 2025, Catalent Indiana, LLC (part of Novo Nordisk) ("Catalent Indiana") informed Scholar Rock Holding Corporation (the "Company") that, following the Form FDA 483 issued to Catalent Indiana, LLC on July 14, 2025, the U.S. Food and Drug Administration (the "FDA") determined that the inspection classification of this facility is "official action indicated." Catalent Indiana has since informed the Company that Catalent Indiana received a warning letter from the FDA (the "warning letter"). Catalent Indiana continues to work with the FDA to resolve the outstanding issues cited in the warning letter. Based on the November 12, 2025 Type A Meeting and currently available information from Catalent Indiana, the Company continues to anticipate resubmission of its biologics license application and U.S. launch of apitegromab in spinal muscular atrophy, following approval, in 2026. Cautionary Notes on Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "anticipate," "believe," "expect," "intend," "plan," "seek," "see," "will," "would," "may," "target," and similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding Catalent Indiana's response to the FDA, the Company's regulatory submissions and anticipated approvals, and the impact of any further action by the FDA. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and ass